These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 29717617)

  • 1. Selegiline Nanoformulation in Attenuation of Oxidative Stress and Upregulation of Dopamine in the Brain for the Treatment of Parkinson's Disease.
    Kumar S; Dang S; Nigam K; Ali J; Baboota S
    Rejuvenation Res; 2018 Oct; 21(5):464-476. PubMed ID: 29717617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biopharmaceutical Potential of Selegiline Loaded Chitosan Nanoparticles in the Management of Parkinson's Disease.
    Rukmangathen R; Yallamalli IM; Yalavarthi PR
    Curr Drug Discov Technol; 2019; 16(4):417-425. PubMed ID: 29669501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of intranasally administered selegiline nanoparticles with improved brain delivery in Parkinson's disease.
    Sridhar V; Gaud R; Bajaj A; Wairkar S
    Nanomedicine; 2018 Nov; 14(8):2609-2618. PubMed ID: 30171904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Designing lisuride intranasal nanocarrier system for reduction of oxidative damage with enhanced dopamine level in brain for Parkinsonism.
    Kumar S; Gupta SK; Pahwa R
    J Psychiatr Res; 2023 Sep; 165():205-218. PubMed ID: 37517241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method.
    Md S; Haque S; Fazil M; Kumar M; Baboota S; Sahni JK; Ali J
    Expert Opin Drug Deliv; 2014 Jun; 11(6):827-42. PubMed ID: 24655115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amelioration of oxidative stress utilizing nanoemulsion loaded with bromocriptine and glutathione for the management of Parkinson's disease.
    Usama Ashhar M; Vyas P; Vohora D; Kumar Sahoo P; Nigam K; Dang S; Ali J; Baboota S
    Int J Pharm; 2022 Apr; 618():121683. PubMed ID: 35314276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin E loaded resveratrol nanoemulsion for brain targeting for the treatment of Parkinson's disease by reducing oxidative stress.
    Pangeni R; Sharma S; Mustafa G; Ali J; Baboota S
    Nanotechnology; 2014 Dec; 25(48):485102. PubMed ID: 25392203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design Expert(®) supported optimization and predictive analysis of selegiline nanoemulsion via the olfactory region with enhanced behavioural performance in Parkinson's disease.
    Kumar S; Ali J; Baboota S
    Nanotechnology; 2016 Oct; 27(43):435101. PubMed ID: 27655136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuation of Oxidative Damage by Coenzyme Q
    Gupta BK; Kumar S; Kaur H; Ali J; Baboota S
    Rejuvenation Res; 2018 Jun; 21(3):232-248. PubMed ID: 28844183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nano-ropinirole for the management of Parkinsonism: blood-brain pharmacokinetics and carrier localization.
    Mustafa G; Ahuja A; Al Rohaimi AH; Muslim S; Hassan AA; Baboota S; Ali J
    Expert Rev Neurother; 2015 Jun; 15(6):695-710. PubMed ID: 25955028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Characterization of Nasal Delivery of Selegiline Hydrochloride Loaded Nanolipid Carriers for the Management of Parkinson's Disease.
    Mishra N; Sharma S; Deshmukh R; Kumar A; Sharma R
    Cent Nerv Syst Agents Med Chem; 2019; 19(1):46-56. PubMed ID: 30474538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCRD based development of bromocriptine and glutathione nanoemulsion tailored ultrasonically for the combined anti-parkinson effect.
    Ashhar MU; Kumar S; Ali J; Baboota S
    Chem Phys Lipids; 2021 Mar; 235():105035. PubMed ID: 33400967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Appraisal of Transdermal Water-in-Oil Nanoemulgel of Selegiline HCl for the Effective Management of Parkinson's Disease: Pharmacodynamic, Pharmacokinetic, and Biochemical Investigations.
    Setya S; Madaan T; Tariq M; Razdan BK; Talegaonkar S
    AAPS PharmSciTech; 2018 Feb; 19(2):573-589. PubMed ID: 28875405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity.
    Raj R; Wairkar S; Sridhar V; Gaud R
    Int J Biol Macromol; 2018 Apr; 109():27-35. PubMed ID: 29247729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Rutin Nanoemulsion in Ameliorating Oxidative Stress: Pharmacokinetic and Pharmacodynamics Studies.
    Sharma S; Rabbani SA; Narang JK; Hyder Pottoo F; Ali J; Kumar S; Baboota S
    Chem Phys Lipids; 2020 May; 228():104890. PubMed ID: 32032570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ameliorative effect of Sida cordifolia in rotenone induced oxidative stress model of Parkinson's disease.
    Khurana N; Gajbhiye A
    Neurotoxicology; 2013 Dec; 39():57-64. PubMed ID: 23994302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model.
    Md S; Khan RA; Mustafa G; Chuttani K; Baboota S; Sahni JK; Ali J
    Eur J Pharm Sci; 2013 Feb; 48(3):393-405. PubMed ID: 23266466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin E Loaded Naringenin Nanoemulsion via Intranasal Delivery for the Management of Oxidative Stress in a 6-OHDA Parkinson's Disease Model.
    Gaba B; Khan T; Haider MF; Alam T; Baboota S; Parvez S; Ali J
    Biomed Res Int; 2019; 2019():2382563. PubMed ID: 31111044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation.
    Azeem A; Talegaonkar S; Negi LM; Ahmad FJ; Khar RK; Iqbal Z
    Int J Pharm; 2012 Jan; 422(1-2):436-44. PubMed ID: 22057087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.